Canaccord Genuity Reiterates a 'Buy' on Impax Laboratories (IPXL); Our Top Small Cap Pick is Catalyst Heavy

March 14, 2012 8:59 AM EDT Send to a Friend
Get Alerts IPXL Hot Sheet
Price: $27.09 +0.30%

Rating Summary:
    7 Buy, 10 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 29 | Down: 28 | New: 24
Trade IPXL Now!
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Impax Laboratories (NASDAQ: IPXL) price target of $29.00.

Analyst, Randall Stanicky, said, "We hosted meetings with Impax management for the second time in as many weeks as we look to stay close to the story. Our message remains consistent and unchanged – we see a catalyst-heavy near-term path with sentiment we think will continue to improve. The warning letter has cast a cloud on what we think is an inflection year for IPXL as several headwinds (warning letter, Adderall XR supply) are now likely to turn into upside drivers this year while the outlook for 2013 and beyond is still underestimated, in our view...IPXL remains our top small cap generic stock."

For an analyst ratings summary and ratings history on Impax Laboratories click here. For more ratings news on Impax Laboratories click here.

Shares of Impax Laboratories closed at $23.13 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments

Add Your Comment